DA-EPOCH-R方案治疗B细胞非霍奇金淋巴瘤效果观察  

Efficacy observation of DA-EPOCH-R protocol for patients with B-cell non-Hodgkin lymphoma

作　　者：吴尉[1] 邵建华[2] 李大启[2] 董学斌[2] 陈萍[2] 赵红玉[2] 顾琳萍[2] 孙琳[2] 解杰[2] 

机构地区：[1]潍坊医学院临床学院,261053 [2]山东大学附属济南市中心医院血液内科,250013

出　　处：《白血病．淋巴瘤》2017年第4期217-220,共4页Journal of Leukemia & Lymphoma

摘　　要：目的 观察DA-EPOCH-R方案治疗B细胞非霍奇金淋巴瘤（NHL）的效果及安全性.方法 采用DA-EPOCH-R方案治疗43例B细胞NHL患者,观察近期疗效、不良反应,进行随访,分析生存情况.结果 43例NHL患者共接受203个疗程化疗,中位化疗6个（2~8个）疗程.32例（74.4%）化疗2~4个疗程后达完全缓解（CR）.年龄≤60岁与＞60岁、 Ⅰ~Ⅱ期与Ⅲ~Ⅳ期、 生发中心来源（GCB）型与非GCB型、双表型与非双表型患者CR率差异均无统计学意义（均P＞0.05）.中位随访40个月（9~62个月）,1、3年总生存率分别为97.6%、92.8%.不良反应为血液学不良反应,化疗结束后的随访期内未见严重不良反应,未出现继发性第二肿瘤.结论 DA-EPOCH-R方案治疗B细胞NHL CR率较高,Ⅲ、Ⅳ期患者的疗效与Ⅰ、Ⅱ期相近,老年患者耐受性良好.Objective To evaluate the efficacy and safety of DA-EPOCH-R protocol for patients with B-cell non-hodgkin lymphoma （NHL）. Methods 43 patients with B-cell NHL received DA-EPOCH-R protocol, and their efficacy and adverse reactions were analyzed. Results 43 patients received a total of 203 cycles of chemotherapy and the median chemotherapy cycle was 6 （2ˉ8 cycles）. 32 patients （74.4%） achieved complete remission （CR） after 2ˉ4 cycles of chemotherapy. A further analysis found that age ≤60 years and〉60 years, stageⅠ/Ⅱand stageⅢ/Ⅳ, germinal center B-cell （GCB）, non-GCB, double expression lymphoma （DEL） and non-DEL patients had no significant differences （P〉 0.05）. With a median follow-up of 40 months （9ˉ62 mouths）, the overall survival （OS） rate of 1-year and 3-year was 97.6 % and 92.8 % respectively. The major toxicity of DA-EPOCH-R protocol was hematologic toxicity. Other toxicities were mild, and no treatment-related deaths occurred. At the end of follow-up, no secondary tumors were found. Conclusions DA-EPOCH-R protocol is an effective and safe protocol for patients with NHL. The result shows that the curative effect of patients in stageⅢandⅣis similar to the patients in stageⅠandⅡ.

关 键 词：淋巴瘤 非霍奇金 DA-EPOCH-R方案 双表型淋巴瘤 

分 类 号：R733.1[医药卫生—肿瘤]